Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,874.00
(
-0.31%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
91.50
(
-1.25%
)
Bitcoin
76,549.47
(
3.64%
)
News Focus
News Focus
Post# of 257430
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122879
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 02/11/2021 8:41:02 AM

Thursday, February 11, 2021 8:41:02 AM

Post# of 257430
BVS IPOs 9.20M* Class-A shares @$13.00:

https://www.globenewswire.com/news-release/2021/02/11/2173678/0/en/Bioventus-Announces-Pricing-of-Initial-Public-Offering.html

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely… [including]…offerings for osteoarthritis, surgical and non-surgical bone healing.

BVS is structured as a holding company, whereby BVS shareholders (after the IPO) will own a 69.5% stake in Bioventus LLC, the sole operating company; the remaining 30.5% stake in Bioventus LLC is owned by a subsidiary of SNN. (Hence, the two classes (A and B) of common shares in BVS.)

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today